Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 3/20 | 0.32 |
| ▸ | CTSV | O60911 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451252 | 1.00 | TRPV1 (0.38) | TRPV1RXFP1NPC1RAB9AKMT2A | |
| SCHEMBL1451779 | 0.95 | TRPV1 (0.39) | TRPV1RXFP1 | |
| SCHEMBL1451775 | 0.95 | TRPV1 (0.39) | TRPV1RXFP1 | |
| SCHEMBL1452407 | 0.89 | TRPV1 (0.37) | TRPV1RXFP1 | |
| SCHEMBL1452412 | 0.89 | TRPV1 (0.37) | TRPV1RXFP1 | |
| SCHEMBL1451186 | 0.87 | TRPV1 (0.37) | TRPV1NPC1RAB9AKMT2A | |
| SCHEMBL1451749 | 0.87 | TRPV1 (0.38) | TRPV1RXFP1CTSLCTSVCTSB | |
| SCHEMBL1451741 | 0.87 | TRPV1 (0.38) | TRPV1RXFP1CTSLCTSVCTSB | |
| SCHEMBL1451625 | 0.86 | TRPV1 (0.45) | TRPV1NPC1RAB9AKMT2ACTSL | |
| SCHEMBL1451628 | 0.86 | TRPV1 (0.45) | TRPV1NPC1RAB9AKMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | claimed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | claimed |
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | MOCHIDA PHARMACEUTICAL CO.,LTD (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | TRPV1 2518/4885RXFP1 432/4885NPC1 2542/4885 |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885RXFP1 336/4885NPC1 2771/4885 |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885RXFP1 336/4885NPC1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.